See more : Crescent Capital BDC, Inc. (CCAP) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (0SAN.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Rapac Communication & Infrastructure Ltd (RPAC.TA) Income Statement Analysis – Financial Results
- Lucero Energy Corp. (LOU.V) Income Statement Analysis – Financial Results
- Saudi Marketing Company (4006.SR) Income Statement Analysis – Financial Results
- Collins Co., Ltd. (2906.TW) Income Statement Analysis – Financial Results
- ShinHsiung Natural Gas Inc. (8908.TWO) Income Statement Analysis – Financial Results
Sandoz Group AG (0SAN.L)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.60B | 8.83B | 8.55B |
| Cost of Revenue | 5.42B | 4.56B | 4.63B | 4.60B |
| Gross Profit | 4.56B | 4.05B | 4.20B | 3.95B |
| Gross Profit Ratio | 45.74% | 47.04% | 47.52% | 46.17% |
| Research & Development | 926.00M | 45.30M | 831.11M | 772.88M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 1.97B | 0.00 | 0.00 |
| SG&A | 2.39B | 1.97B | 1.94B | 1.89B |
| Other Expenses | 874.00M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.19B | 2.95B | 2.94B | 3.26B |
| Cost & Expenses | 9.60B | 7.51B | 7.58B | 7.86B |
| Interest Income | 31.00M | 74.89M | 54.74M | 61.09M |
| Interest Expense | 202.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 525.00M | 389.25M | 406.89M | 573.68M |
| EBITDA | 857.00M | 1.53B | 1.68B | 1.28B |
| EBITDA Ratio | 8.59% | 17.84% | 19.01% | 15.01% |
| Operating Income | 375.00M | 1.15B | 1.27B | 710.02M |
| Operating Income Ratio | 3.76% | 13.31% | 14.40% | 8.30% |
| Total Other Income/Expenses | -245.00M | -137.00M | -196.15M | -176.97M |
| Income Before Tax | 130.00M | 1.02B | 1.20B | 625.03M |
| Income Before Tax Ratio | 1.30% | 11.84% | 13.57% | 7.31% |
| Income Tax Expense | 50.00M | 233.00M | 367.66M | 214.25M |
| Net Income | 77.00M | 784.05M | 828.37M | 409.01M |
| Net Income Ratio | 0.77% | 9.11% | 9.38% | 4.78% |
| EPS | 0.18 | 1.82 | 1.92 | 0.95 |
| EPS Diluted | 0.18 | 1.82 | 1.92 | 0.95 |
| Weighted Avg Shares Out | 429.90M | 430.46M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 429.90M | 431.00M | 431.00M |
Source: https://incomestatements.info
Category: Stock Reports